Current Report Filing (8-k)
October 14 2020 - 9:14AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 14, 2020
INTERPACE
Biosciences, INC.
(Exact
name of Registrant as specified in its charter)
DELAWARE
|
|
0-24249
|
|
22-2919486
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
Morris
Corporate Center 1, Building C
300
Interpace Parkway,
Parsippany,
NJ 07054
(Address,
including zip code, of Principal Executive Offices)
(855)
776-6419
Registrant’s
telephone number, including area code:
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, $0.01
par value per share
|
|
IDXG
|
|
The Nasdaq Stock
Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
[ ]
Emerging growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
On
October 14, 2020, Interpace Biosciences, Inc. (the “Company”) announced that the Audit Committee of the Board of Directors
has completed an independent investigation into complaints of certain employment and billing and compliance matters and concluded
that the allegations made in the complaints are unsubstantiated and that there was no evidence of any illegal acts.
As
set forth in the Company’s Notification of Late Filing on Form 12b-25, filed with the U.S. Securities and Exchange Commission
on August 14, 2020, announcing the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarter
ended June 30, 2020, in July 2020, the Company received letters from employees, one of whom has left the Company’s employ,
concerning certain employment and billing and compliance matters. In response, the Company informed its Audit Committee and Regulatory
Compliance Committee as well as its independent registered public accounting firm. The Audit Committee commenced an investigation
of these matters with the assistance of independent counsel and advisors thereto. The Audit Committee concluded that the allegations
were not substantiated and that there was no evidence of any illegal acts.
The
full text of the press release is set forth as Exhibit 99.1 attached hereto.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Interpace
Biosciences, Inc.
|
|
|
|
|
By:
|
/s/
Jack E. Stover
|
|
Name:
|
Jack E. Stover
|
|
Title:
|
President and Chief
Executive Officer
|
Date:
October 14, 2020
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024